Temat: mTOR inhibitors - Katalog OPAC zbiorów

Skocz do pozycji: 1.

Tytuł:: The mTOR signalling pathways in the pathogenesis and treatment of neuroendocrine tumours
Autorzy:: Kolasińska-Ćwikła, Agnieszka
Powiązania:: https://bibliotekanauki.pl/articles/1064993.pdf
Data publikacji:: 2016
Wydawca:: Medical Education
Tematy:: mTOR inhibitors
mTOR signalling pathway
neuroendocrine tumours (NETs)
Opis:: Neuroendocrine tumours (NET) are a rare and heterogeneous group of neoplasms. The majority of patients are diagnosed with locally advanced or metastatic disease, and curative surgery is rarely an option. Treatment approaches involving targeted therapy, including the use of agents inhibiting the mTOR signalling pathways involved in neuroendocrine tumourigenesis, provide new therapeutic options for patients with NETs.
Źródło:: OncoReview; 2016, 6, 1; A37-42
2450-6125
Pojawia się w:: OncoReview
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 2.

Tytuł:: Everolimus in every day practice of metastatic renal cell carcinoma therapy – one center experience
Autorzy:: Huszno, Joanna
Nowara, Elżbieta
Powiązania:: https://bibliotekanauki.pl/articles/1064863.pdf
Data publikacji:: 2016
Wydawca:: Medical Education
Tematy:: clinicopathological factors
mRCC
mTOR inhibitors
toxicity
Opis:: Introduction: Everolimus is a selective mTOR inhibitor which received approval for treatment of advanced renal cell carcinoma (mRCC) after progression on or after treatment with VEGF-targeted therapy. The aim of this study was to evaluate the efficiency and toxicity profile of everolimus in second line therapy of mRCC. The authors also assessed the impact of clinicopathological factors on the effectiveness of everolimus. Methods: The retrospective analysis was conducted on the medical records of 33 mRCC patients who were treated with everolimus in second line therapy after progression on interferon or tyrosine kinase inhibitors (sunitinib or pazopanib) during the years 2010–2016. Results: Median time of treatment with everolimus was 4 months (range from 1 to 58 months). Median progression free survival was 4 months and overall survival (OS) was 11 months. The best response (PR + CR + SD) was reported in 57% of patients. Toxicity in grade 3–4 was reported in 9 (27%) of patients. Clinicopathological factors associated with progression during everolimus therapy were: smoking and alcohol abuse (p = 0.029), higher Furman grade (p = 0.166), tumor necrosis (p = 0.383), fat tissue infiltration (p = 0.040), lymph node (p = 0.193) and adrenal metastases (p = 0.067). Factors which increase the risk of everolimus toxicity were worse performance status (p = 0.333) and more advanced disease at the beginning (lymph nodes metastases, p = 0.05) and higher Furman grade (p = 0.04). Conclusions: Cigarettes use and/or alcohol abuse, adrenal metastases, fat tissue had significantly negative influence on survival. Grade 3–4 toxicity were reported more frequently in patients with worse performance status and more advanced disease at the time of diagnosis.
Źródło:: OncoReview; 2016, 6, 3; A143-148
2450-6125
Pojawia się w:: OncoReview
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Informacja

Wyszukujesz frazę "mTOR inhibitors" wg kryterium: Temat

Źródło danych

Dostawca treści

Kolekcja

Rok wydania

Wydawca

Temat

Autor

Typ dokumentu

Język